However, it was recently shown that SMS2 but not SMS1 was upregulated in ovarian cancer tissues and cell lines and, consequently, SMS2 overexpression promoted cancer cell growth and migration [99], suggesting a therapeutic function of SMS2 inhibition in ovarian cancer treatment. Here, SGMS1 is linked to ovarian cancer.